Several clinical trials have tested the therapeutic potential of ETA antagonists in CKD, and early-phase clinical trials suggest that ETA antagonists might be beneficial as nephroprotective and antiproteinuric drugs for diabetes, hypertensive nephropathy, and CKD (411–414). The gene discussed is EDNRA; the disease is hypertensive nephropathy.